Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo

    NEXT STORY
    Delcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019
    PREV STORY
    MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio

    LAVAL, Quebec, and ORLEANS, Ontario, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Crescita Therapeutics Inc. ...

    author_avatar
    NASDAQ Market News

    Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery

    author_avatar
    NASDAQ Market News

    ASLAN Pharmaceuticals’ Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer

    author_avatar
    NASDAQ Market News